Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

Journal of Virology

Volumn 68, Issue 3, 1994, Pages 1660-1666

  Richman, Douglas D ^a,b   Havlir, Diane ^a   Corbeil, Jacques ^a   Looney, David ^a,b   Ignacio, Caroline ^a   Spector, Stephen A ^a   Sullivan, John ^c   Cheeseman, Sarah ^c   Barringer, Kevin ^d   Pauletti, Dan ^d   Shih, Cheng Kon ^d   Myers, Maureen ^d   Griffin, Johanna ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DNA SEQUENCE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION;

EID: 0027957791     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.68.3.1660-1666.1994     Document Type: Article

References (35)

1. Bacolla, A., C.-K. Shih, J. M. Rose, G. Piras, T. C. Warren, C. A. Grygon, R. H. Ingraham, R. C. Cousins, D. J. Greenwood, D. Richman, Y.-C. Cheng, and J. A. Griffin. 1993. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2: effect on kinetic constants and inhibition by nonnucleoside analogs. J. Biol. Chem. 268:16571-16577.
2. Balzarini, J., A. karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
3. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, B. S. Wolanski, D. J. Graham, L. Gotlib, A. Rhodes, D. L. Titus, E. Roth, O. M. Blahy, J. C. Quintero, S. Staszewski, and E. A. Emini. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
4. Cheeseman, S. H., and The ACTG 164/168 Study Team. 1992. Nevirapine (NVP) alone and in combination with zidovudine, abstr. M.B0053. VIII International Conference on AIDS/III STD World Congress. Amsterdam. The Netherlands, 19 to 24 July.
5. Cheeseman, S. H., S. E. Hattox, M. M. McLaughlin, R. A. Koup, C. Andrews, C. A. Bova, J. W. Pav, T. Roy, J. L. Sullivan, and J. J. Keirns. 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37:178-182.
6. Coffin, J. M. 1992. Genetic diversity and evolution of retroviruses. Curr. Top. Microbiol. Immunol. 176:143-164.
7. Corpet, F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16:10881-10890.
8. Daar, E. S., T. Moudgil, R. D. Meyer, and D. D. Ho. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-964.
9. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A novel mutation in bisheteroarylpiperazine-resistant HIV-1 reverse transcriptase confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. 90:4713-4717.
10. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Tacz, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 362:359-362.
11. Emini, E. A., D. J. Graham, L. Gotlib. J. H. Condra, V. W. Byrnes, and W. A. Schleif. 1993. HIV and multidrug resistance. Nature (London) 364:679.
12. Eron, J. J., Jr., V. A. Johnson, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1. including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
13. Gao, W.-Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-2333.
14. Havlir, D., and The ACTG 164 and 168 Study Teams. 1993. Antiviral activity of nevirapine at 400 mg in p24 antigen positive adults, p. 69. abstr. WS-B26-1. IXth International Conference on AIDS/IVth STD World Congress, Berlin, Germany, 6 to 11 June 1993.
15. Holland, J. J., J. C. De La Torre, and D. A. Steinhauer. 1992. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176:1-20.
16. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164:646-655.
17. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
18. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
19. Larder, B. A. 1992. 3′-Azido-3′-deoxthymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
20. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (London) 365:451-453.
21. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
22. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
23. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
24. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 362:355-358.
25. Piatak, M., Jr., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
26. Richman, D., A. S. Rosenthal, M. Skoog, R. J. Eckner, T.-C. Chou, J. P. Sabo, and V. J. Merluzzi. 1991. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35: 305-308.
27. Richman, D. D., V. A. Johnson, D. L. Mayers, T. Shirasaka, M. C. O'Brien, and H. Mitsuya. In vitro evaluation of experimental agents for anti-HIV activity. In J. E. Coligan, A. M. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, in press. J. Wiley, New York.
28. Richman, D. D., T.-C. Meng, S. A. Spector, M. A. Fischl, L. Resnick, and S. Lai. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr., in press.
29. Richman, D. D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. HIV-1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
30. Saag, M. S., E. A. Kmini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw, and The L-697, 661 Working Group. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
31. Sardana, V. V., E. Emini, L. Gotlib, D. J. Graham, D. W. Lineberger, W. J. Long, A. J. Schlabach, J. A. Wolfgang, and J. H. Condra. 1992. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 267:17526-17530.
32. Shih, C.-K., J. M. Rose, G. L. Hansen, J. C. Wu, A. Bacolla, and J. A. Griffin. 1991. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proc. Natl. Acad. Sci. USA 88:9878-9882.
33. Spector, S. A., C. Kennedy, J. A. McCutchan, S. A. Bozzette, R. C. Straube, J. D. Connor, and D. D. Richman. 1989. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J. Infect. Dis. 159:822-828.
34. St. Clair, M., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
35. Wu, J. C., T. C. Warren, J. Adams, J. Proudfoot, J. Skiles, P. Raghaven, C. Perry, I. Potocki, P. R. Farina, and P. M. Grob. 1991. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 30:2022-2026.